Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (5): 417-425.DOI: 10.5246/jcps.2023.05.035
• Drug administration and clinical pharmacy column • Previous Articles Next Articles
Min Wan1, Jinyu Liu2, Guangyi Yu1, Suiju Tong1, Lei Ke3, Yu Zhang3, Ruxu You3,*()
Received:
2022-09-06
Revised:
2022-11-29
Accepted:
2022-12-08
Online:
2023-06-02
Published:
2023-06-02
Contact:
Ruxu You
Supporting:
Min Wan, Jinyu Liu, Guangyi Yu, Suiju Tong, Lei Ke, Yu Zhang, Ruxu You. Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 417-425.
[1] |
Consensus development conference: prophylaxis and treatment of osteoporosis. Am. J. Med. 1991, 90, 107–110.
|
[2] |
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South. Med. J. 2001, 94, 569–573.
|
[3] |
Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin. J. Osteoporos. 2019, 25, 281–309.
|
[4] |
Si, L.; Winzenberg, T.M.; Jiang, Q.; Chen, M.; Palmer, A.J. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int. 2015, 26, 1929–1937.
|
[5] |
National Bureau of Statistics of the People's Republic of China. China Statistical Yearbook. Beijing: China Statistics Press. 2020.
|
[6] |
Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis. Chin. J. Osteoporos. 2019, 25, 281–309.
|
[7] |
Kheder, S.; Ali, H.M. Medicine prices, availability, affordability and price components in Sudan. World Health Organization. 2014.
|
[8] |
Zhang, Y.; Li, X. Investigation and analysis of availability and affordability of essential medicine in Nanjing based on WHO/HAI standard survey method. China Pharm. 2015, 26, 4188–4192.
|
[9] |
Wang, X.; Yang, S.M.; Fang, Y.; Jiang, M.H.; Wu, L.N. Study on the availability and price of pediatric essential medicines in public hospitals in Shaanxi Province using WHO/HAI methodology. China Pharm. 2014, 25, 681–684.
|
[10] |
Dong, Z.J.; Tao, Q.C.; Yan, B.B.; Sun, G.J. Availability, prices and affordability of essential medicines in Zhejiang Province, China. PLoS One. 2020, 15, e0241761.
|
[11] |
Gong, S.W.; Cai, H.B.; Ding, Y.F.; Li, W.J.; Juan, X.; Peng, J.L.; Jin, S. The availability, price and affordability of antidiabetic drugs in Hubei Province, China. Health Policy Plan. 2018, 33, 937–947.
|
[12] |
Department of Human Resources and Social Security of Hubei Province. Circular of the General Office of the Provincial People’s Government on Adjusting the Provincial Minimum Wage Standard. 2021 [EB/OL]. (2021-08-31). This article can be found online at http://www.hubei.gov.cn/zxjy/rdhy/202108/t20210831_3730793.shtml.
|
[13] |
You, R.; Liu, Z. Economic evaluation of oral alendronate therapy for osteoporosis in Chinese postmenopausal women: the impact of medication compliance and persistence. Front. Pharmacol. 2020, 11, 575893.
|
[14] |
You, R.; Zhang, Y.; Wu, D.B.; Liu, J.; Qian, X.; Luo, N.; Mori, T. Cost-effectiveness of zoledronic acid versus oral alendronate for postmenopausal osteoporotic women in China. Front. Pharmacol. 2020, 11, 456.
|
[15] |
Eastell, R.; Rosen, C.J.; Black, D.M.; Cheung, A.M.; Murad, M.H.; Shoback, D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society. J. Clin. Endocrinol. Metab. 2019, 104, 1595–1622.
|
[16] |
Mori, T.; Crandall, C.J.; Ganz, D.A. Cost-effectiveness of combined oral bisphosphonate therapy and Falls prevention exercise for fracture prevention in the USA. Osteoporos. Int. 2017, 28, 585–595.
|
[17] |
Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Arch. Osteoporos. 2021, 16, 113.
|
[18] |
Li, N.N.; Cornelissen, D.; Silverman, S.; Pinto, D.; Si, L.; Kremer, I.; Bours, S.; de Bot, R.; Boonen, A.; Evers, S.; van den Bergh, J.; Reginster, J.Y.; Hiligsmann, M. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. PharmacoEconomics. 2021, 39, 181–209.
|
[19] |
Cosman, F.; Nieves, J.W.; Dempster, D.W. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J. Bone Miner. Res. 2017, 32, 198–202.
|
[20] |
Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch. Osteoporos. 2021, 16, 72.
|
[21] |
Lv, F.B.; Yu, K.W.; Gao, W.W.; Yu, S.W. Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 2017, 26, 447–454.
|
[22] |
Chen, J.; Zhao L.B.; Wan Y.S.; Wang L.; Lv, Y.N.; Zhang, Y.; You, R.X. Rapid health technology assessment of treating osteoporosis with alendronate. Chin. J. Hospital Pharmacy. 2021, 41, 2227–2235.
|
[23] |
Wang, H. Analysis on the principal component of the factors which effected medicine prices in China. Chin. Health Econ. 2018, 37, 71–73.
|
[24] |
Luo, S.H.; Dong, L.L.; Li, Y.Y.; Xu, D.; Chen, M. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer. J. Chin. Pharm. Sci. 2021, 30, 253–263.
|
[1] | Xiuwei Yang, Youbo Zhang, Wei Xu. Determination and pharmacokinetic study of p-hydroxyphenethyl anisate following intravenous and oral administration in rats by RP-HPLC method [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(11): 804-812. |
[2] | Yajie Yin, Xiaofei Zhang, Zheng Cui, Wei Qu, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang. In vitro dissolution and oral bioavailability study of fenofibrate nanomatrix system prepared by hot-melt extrusion [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 329-338. |
[3] | Zhengsheng Liu, Haijun Hao, Mingsong Fan. Quercetin-phospholipids complex solid dispersion and quercetin solid dispersion: preparation and evaluation [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(12): 868-877. |
[4] | Jinfeng Zhang, Fan Wu, Jiayi Han, Jinghong Rong, Yi Li, Yu Liu, Xiao Liang, Xin Wang, Hao Pan, Hongsheng Liu, Lijiang Chen. Preparation, characterization and pharmacokinetic studies of total paeony glycoside nanocrystals [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 99-108. |
[5] | Xinguo Zhang, Jinweng Liu, Fei Kou, Qianglin Wang, Ziyu Liu, Jianyong Li. Bioavailability and pharmacokinetics of alantolactone from Inula helenium in rats following intravenous and oral administrations [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(4): 284-290. |
[6] | Zhou Wen, Shan Ji, Feifan Xie, Gaoyun Hu, Zeneng Cheng. Determination of mefunidone, a novel anti-fibrotic agent analogue of pirfenidone, in plasma by HPLC-UV and its pharmacokinetic application in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(1): 45-52. |
[7] | Xianchuang Wu, Haijun Hao, Yuxin Liu, Xiaoyong Song, Yongzhou Zhang, Hongqin Zhang. Bioavailability of 10-hydroxycamptothecin-phospholipid complex loaded by solid dispersion and lipid-based formulations [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(12): 780-788. |
[8] | Haijun Hao*, Youzhi Jia, Ru Han. Phytosomes: an effective approach to enhance the oral bioavailability of active constituents extracted from plants [J]. , 2013, 22(5): 385-392. |
[9] | Yan-Jiao Li, Hui-Min Liu, Xiao-Fang Dang, Shuo-Feng Zhang, Jin-Ying Wu, Zhan-Hong Jia, Li-Wei Han*. A pharmacokinetic study of puerarin formulated in mixed micelles in Beagle dogs by HPLC [J]. , 2012, 21(4): 327-332. |
[10] | Ya-Ou Liu, Jie-Ming Fan, Xue-Qing Wang*, Qiang Zhang. Preparation of sorafenib self-microemulsifying drug delivery system and its relative bioavailability in rats [J]. , 2011, 20(2): 164-170. |
[11] | Xin-Ru Li, Yu-Sheng Pei, Yan-Qing Huang, Yan-Xia Zhou, Yu-Chen Zhang, Yan Liu* . In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for silybin [J]. , 2009, 18(4): 342-347. |
[12] | Ning Tang, Jie Lai, Ya-Pin Chen, Yi Lu*, Wei Wu*. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs [J]. , 2009, 18(2): 156-161. |
[13] |
Xue-Wei Song, Zhi-Hang Chen, Jin-Jing Che, Cheng-Qi Shan, Yu-Nan Hou, Ren-Jiu Zheng, Yuan-Guo Cheng*. Pharmacokinetics of recombinant human parathyroid hormone after subcutaneous administration in Rhesus monkeys by immunoradiometric assay [J]. , 2008, 17(2): 118-121. |
[14] |
Lian-Dong Hu*, Cheng-Wei Wang .
Preparation and bioavailability in healthy volunteers of cefaclor modified-release capsules
[J]. , 2007, 16(1): 57-60.
|
[15] | XIAO Hong*, SHEN Hong, CHEN Jian-fang, XIAO Da-wei. Determination of Lovastatin Level in Human Plasma and Lovastatin Capsules Bioavailability in Healthy Volunteers Using HPLC-MS [J]. , 2006, 15(4): 233-237. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||